Omeprazole

Introduction Overview

Generic Name

omeprazole

Brand Name

Prilosec

Dosage Form

oral capsule, oral delayed-release tablet, oral suspension (powder for reconstitution)

Drug Class

Proton pump inhibitors

Pharmacokinetics

Absorption:
Omeprazole, the active ingredient in Prilosec, is rapidly absorbed after oral administration with peak plasma concentrations typically achieved within 0.5 to 3.5 hours post-dose. The bioavailability of omeprazole is approximately 30-40% after a single dose due to extensive first-pass metabolism in the liver; however, with repeated dosing, bioavailability can increase due to reduced first-pass metabolism possibly via enzyme inhibition. Absorption occurs primarily in the small intestine since omeprazole is acid-labile and formulated as delayed-release granules or enteric-coated capsules to resist gastric degradation.

Distribution:
Omeprazole is moderately bound to plasma proteins at approximately 95%, mainly to albumin. The volume of distribution ranges from 0.3 to 0.5 L/kg indicating moderate tissue penetration. Omeprazole penetrates into gastric parietal cells where it exerts its therapeutic action. Limited studies indicate that omeprazole can cross the placental barrier and is excreted minimally into breast milk.

Metabolism:
Omeprazole undergoes extensive hepatic metabolism primarily via the cytochrome P450 enzyme CYP2C19 and to a lesser extent CYP3A4. The metabolism involves hydroxylation and sulfoxidation to inactive metabolites, predominantly hydroxyomeprazole. Genetic polymorphisms in CYP2C19 can significantly affect plasma levels, with poor metabolizers exhibiting higher systemic exposures and prolonged half-lives.

Elimination:
The elimination half-life of omeprazole is approximately 1 to 1.5 hours after a single dose but may be prolonged in poor metabolizers or hepatic impairment. Excretion occurs mainly via the urine (about 80%), with metabolites eliminated through both renal and fecal routes. Less than 5% of the unchanged drug is recovered in urine, indicating nearly complete metabolism prior to excretion.

Dosage Forms

Available Dosage Forms:
- Oral delayed-release capsules: 10 mg, 20 mg, and 40 mg
- Oral delayed-release tablets: 20 mg and 40 mg
- Oral suspension (powder for reconstitution): 2.5 mg/mL and 4 mg/mL
- Over-the-counter (OTC) delayed-release tablets: 20 mg

Dosages for Adults and Adolescents:
- Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis: 20 mg once daily for 4 to 8 weeks; may increase to 40 mg once daily if necessary
- Maintenance of healed erosive esophagitis: 20 mg once daily
- Duodenal Ulcer Treatment: 20 mg once daily for 2 to 4 weeks
- Helicobacter pylori eradication (in combination with antibiotics such as amoxicillin and clarithromycin): 20 mg twice daily for 10 to 14 days
- Zollinger-Ellison Syndrome or other pathological hypersecretory conditions: Initial dose 60 mg daily, individual titration may be required

Specific Patient Populations:
- Pediatric patients: Safety and efficacy established in children aged 1 to 16 years for short-term treatment of GERD and erosive esophagitis, with dosages adjusted based on weight (typically 10-20 mg once daily)
- Patients with hepatic impairment: Dose reduction recommended due to decreased clearance and prolonged half-life
- Elderly: No initial dosage adjustment; monitor for adverse effects
- Renal impairment: No dosage adjustment required

Clinical Guidelines:
Prilosec OTC is indicated for adult patients for relief of frequent heartburn occurring 2 or more days per week; the recommended dose is 20 mg once daily for 14 days. The course should not be repeated more frequently than every 4 months without consulting a healthcare provider.

Mechanism Of Action

Omeprazole, the active compound in Prilosec, is a proton pump inhibitor (PPI) that selectively and irreversibly inhibits the hydrogen/potassium adenosine triphosphatase enzyme system (H+/K+ ATPase) located on the secretory surface of gastric parietal cells. This enzyme is the final step of acid production in the stomach. By binding covalently to the cysteine residues of the ATPase enzyme, omeprazole prevents the transport of hydrogen ions into the gastric lumen, thereby effectively suppressing gastric acid secretion.

The drug is a prodrug, activated in the acidic environment of the secretory canaliculi of parietal cells, and forms a sulfenamide intermediate that covalently modifies and inhibits the proton pump. This inhibition is irreversible for the lifespan of the proton pump; therefore, acid secretion is suppressed until new pumps are synthesized, resulting in prolonged duration of action beyond the plasma half-life.

At the cellular level, this potent blockade decreases gastric acidity, providing symptomatic relief of acid-related diseases and creating a favorable environment for healing erosive esophagitis and ulcers. The suppression of acid facilitates eradication of H. pylori when used in combination with appropriate antibiotics by increasing gastric pH and thereby stabilizing antibiotics sensitive to acidic degradation.

Compared to histamine-2 receptor antagonists (H2RAs), omeprazole provides a more profound and longer-lasting inhibition of gastric acid secretion. Clinical studies support its superior efficacy in healing GERD and reducing acid-related symptoms. Research has also demonstrated that long-term therapy with omeprazole markedly reduces gastric acid secretion, although clinicians must consider potential risks such as gastric mucosal changes or nutrient malabsorption.

Pharmacological Actions

Suppression of gastric acid secretion through irreversible inhibition of the H+/K+ ATPase proton pump in gastric parietal cells.
Increase in gastric pH leading to symptomatic relief of acid-related disorders such as gastroesophageal reflux disease (GERD) and erosive esophagitis.
Facilitation of Helicobacter pylori eradication when used adjunctively with antibiotics by improving antibiotic stability and efficacy.
Reduction in gastric acid-mediated injury and inflammation promoting mucosal healing in gastric and duodenal ulcers.
Long duration of action due to covalent binding, leading to sustained acid suppression beyond plasma half-life.
Influences absorption of certain drugs requiring acidic environment for dissolution and bioavailability.
Modulation of gastric microbiome dynamics through altering stomach acidity.
Possible alteration of bone metabolism by affecting calcium absorption, linked to increased fracture risk with prolonged use.
Associated impact on magnesium absorption, potentially causing hypomagnesemia with chronic therapy.
Potential immunomodulatory properties contributing to changes in infection susceptibility.
Inhibition of nocturnal and meal-stimulated acid secretion, contributing to improved symptom control in acid reflux.
Improvement in gastric mucosal healing rates in erosive esophagitis compared to other acid suppressants.
Minimal systemic anticholinergic or histaminic side effects due to selective proton pump targeting.
Interaction with cytochrome P450 enzymes affecting metabolism of concomitant medications.

Therapeutic Or Clinical Uses

Treatment of gastroesophageal reflux disease (GERD) including symptomatic relief and healing of erosive esophagitis.
Management of gastric and duodenal ulcers, facilitating mucosal healing.
Eradication of Helicobacter pylori infection in combination with appropriate antibiotic regimens.
Prevention and treatment of ulcers associated with nonsteroidal anti-inflammatory drug (NSAID) therapy.
Treatment of Zollinger-Ellison syndrome and other pathological hypersecretory conditions.
Relief and prevention of frequent heartburn when taken as over-the-counter therapy.
Used in combination therapy for eradication of H. pylori to reduce recurrence of peptic ulcers.
Off-label usage in conditions such as Barrett's esophagus to reduce acid exposure and progression risk.
Management of erosive esophagitis to prevent complications such as strictures and bleeding.
Treatment of acid-related dyspepsia and functional heartburn with acid suppression.
Use in patients with upper gastrointestinal bleeding secondary to acid-related disease.
Reduction of aspiration pneumonia risk by decreasing gastric acidity in select clinical scenarios.
Adjunct treatment in conditions complicated by acid-induced mucosal injury, such as gastritis.
Management of Zollinger-Ellison syndrome to suppress excessive gastric acid secretion and prevent complications.
Short-term treatment of pathological hypersecretory states requiring profound acid suppression.

Side Or Adverse Effects

Common gastrointestinal disturbances including nausea, vomiting, diarrhea, abdominal pain, and flatulence.
Headache and dizziness reported frequently, particularly during initiation of therapy.
Upper respiratory symptoms such as nasal congestion, sore throat, and cough especially in pediatric patients.
Hypomagnesemia manifesting as muscle cramps, spasms, irregular heartbeat, and dizziness, particularly with long-term use.
Increased risk of Clostridium difficile infection associated with altered gastric acidity and microbiome changes.
Potential acute interstitial nephritis leading to renal impairment, with symptoms including reduced urine output and hematuria.
Possible fundic gland polyps development with prolonged use, generally considered benign but may require monitoring.
Rare cases of Stevens-Johnson syndrome and other severe dermatologic reactions including rash and urticaria.
Risk of vitamin B12 deficiency with extended therapy over three years due to reduced gastric acid affecting absorption.
Bone fractures of the hip, wrist, or spine observed more commonly in patients on high dose or long-term therapy.
Joint pain and lupus-like symptoms such as photosensitive rash indicating potential autoimmune effects.
Potential drug-induced liver injury, though rare, may present with elevated liver enzymes.
Allergic reactions including anaphylaxis, angioedema, and swelling of face, lips, tongue, or throat.
Electrolyte disturbances such as low calcium and potassium levels reported in some patients.
Seizures and neurological symptoms have been rarely reported, often in context of severe electrolyte abnormalities.

Precautions

Use with caution in patients with pre-existing liver disease due to altered metabolism and clearance.
Monitor magnesium levels during prolonged therapy especially in patients on concomitant diuretics or with malabsorption.
Assess bone health when long-term therapy is anticipated; supplementation with calcium and vitamin D may be necessary.
Avoid abrupt discontinuation to prevent rebound acid hypersecretion.
Exercise caution in patients with osteoporosis or low bone mineral density to reduce fracture risk.
Consider alternative therapies or specialist referral if symptoms persist beyond 14 days of OTC use or if alarm symptoms occur.
Use cautiously in patients with severe allergic reactions to other proton pump inhibitors or similar compounds.
Assess for underlying conditions mimicking GERD symptoms such as cardiac disease before initiating therapy.
Advise patients about the risk of potential kidney injury; monitor renal function if symptoms suggestive of nephritis occur.
Be aware of potential interactions with CYP2C19 metabolized drugs affecting efficacy or toxicity.
Screen for H. pylori infection in patients requiring long-term acid suppression therapy.
Inform patients about signs of severe diarrhea indicating possible Clostridium difficile infection.
Avoid concomitant use with rilpivirine-containing HIV medications due to absorption and efficacy concerns.
Use caution during pregnancy and breastfeeding; weigh potential benefits against risks due to limited safety data.
Educate patients against sharing medication and emphasize adherence to prescribed dosing to avoid adverse effects.

Warnings

Not intended for immediate relief of heartburn symptoms; onset of action may take 1 to 4 days.
Heartburn symptoms may mimic myocardial infarction; emergency evaluation is imperative if chest pain occurs with other cardiac symptoms.
Risk of acute kidney injury and chronic kidney disease progression; monitor urine output and renal function regularly.
Diarrhea, particularly if watery or bloody, may indicate Clostridium difficile colitis and requires prompt medical evaluation.
Long-term therapy associated with increased risk of bone fractures especially in hip, wrist, or spine.
Potential to induce lupus erythematosus-like symptoms including joint pain and photosensitive rash.
Rare risk of severe allergic reactions including anaphylaxis, angioedema, and bronchospasm.
Overuse or repeated use within shorter intervals than recommended for OTC formulations may increase adverse effects.
May affect absorption of drugs dependent on acidic gastric environment, necessitating review of concomitant medications.
Patients with low magnesium or electrolyte disturbances should be monitored due to risk of arrhythmias.
Possible fundic gland polyp formation with prolonged therapy; clinical significance remains under evaluation.
Vitamin B12 deficiency risk with treatment extending beyond three years; routine monitoring advisable.
Avoid use in patients with known hypersensitivity to omeprazole or related proton pump inhibitors.
Usage in children should be supervised by a healthcare professional due to limited safety information.
Inform patients to report new onset symptoms such as severe stomach pain or seizures immediately.

Contraindication

Known hypersensitivity or allergy to omeprazole or any component of the formulation.
Allergy to other proton pump inhibitors including esomeprazole, lansoprazole, pantoprazole, and rabeprazole.
Previous severe allergic reactions or respiratory distress after taking omeprazole.
Concurrent use with rilpivirine-containing HIV medications such as Complera, Odefsey, Juluca, or Edurant.
Use in patients with unexplained gastrointestinal bleeding or suspicious symptoms until malignancy has been ruled out.
Patients with known hypersensitivity to any inactive ingredients of Prilosec formulation.
Known severe liver impairment without specialized monitoring and dosage adjustment.
Contraindicated in patients unable to swallow capsules or tablets who cannot take alternative formulations safely.
Use contraindicated if history of severe dermatologic reactions to PPIs exists.
Not recommended for infants and children without medical supervision and prescribed indication.
Patients with porphyria should avoid due to potential exacerbation risk.
Use is contraindicated when simultaneous administration with drugs contraindicated with PPIs occurs.
Patients with severe electrolyte imbalances prior to correction should avoid therapy until stable.
Individuals with severe renal impairment should be evaluated before initiation due to altered pharmacokinetics.
Contraindicated when hypersensitivity to esomeprazole or other stereoisomers of omeprazole is confirmed.

Drug Interactions

Clopidogrel: Concomitant use may reduce the antiplatelet effect of clopidogrel due to CYP2C19 inhibition by omeprazole.
Digoxin: Omeprazole may increase digoxin plasma levels by altering gastrointestinal pH and absorption.
Methotrexate: Proton pump inhibitors may reduce elimination of methotrexate, potentially increasing toxicity.
St. John's wort: May induce metabolism enzymes reducing omeprazole efficacy.
Diuretics: Co-administration may increase risk of hypomagnesemia.
Antibiotics such as amoxicillin and clarithromycin: Used concomitantly in tripartite therapy for H. pylori eradication; may influence drug absorption and metabolism.
Rifampin: Induces CYP enzymes causing decreased omeprazole plasma concentrations, reducing therapeutic effect.
HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors: Some may have altered absorption or metabolism when taken with omeprazole.
Warfarin: Possible increased risk of bleeding due to potential elevated INR levels when combined with omeprazole.
Phenytoin and diazepam: Potential increased plasma levels due to CYP2C19 inhibition.
Atazanavir: Reduced absorption when combined with PPIs, potentially decreasing antiviral efficacy.
Tacrolimus: Increased levels reported, potentially increasing nephrotoxicity risk.
Iron salts: Reduced absorption due to higher gastric pH environment.
Ketoconazole and itraconazole: Reduced solubility and absorption with increased gastric pH caused by omeprazole.
Oral contraceptives: Possible reduced efficacy due to altered hepatic metabolism when co-administered.

Preparations Of The Drug

Delayed-release oral capsules containing enteric-coated granules to prevent degradation in stomach acid.
Delayed-release oral tablets formulated with coating to resist acid and allow dissolution in intestine.
Powder for oral suspension (reconstitution required) designed for patients unable to swallow capsules or tablets, with instructions to mix with water and administer immediately or via nasogastric tube.
Over-the-counter (OTC) 20 mg delayed-release tablets for short-term management of frequent heartburn in adults.
Prescription formulations available in multiple dosage strengths including 10 mg, 20 mg, and 40 mg to tailor therapy.
Combination packs containing omeprazole with antibiotics such as amoxicillin and clarithromycin for Helicobacter pylori eradication.
Packaging includes child-resistant bottles or blister packs to enhance medication safety.
Instructions provided for administration with or without food, emphasizing administration before meals for maximal efficacy.
Storage recommendations advise keeping at room temperature, protected from moisture and heat.
Availability of generic omeprazole products with equivalent pharmacological properties and bioequivalence to Prilosec.
Instructions for safely opening capsules and mixing contents with applesauce for patients with swallowing difficulties.
Inclusion of comprehensive medication guides detailing side effects, interactions, and precautions.
Use of inert excipients to improve stability and patient tolerability of formulations.
Special formulations designed for pediatric dosing allowing for accurate weight-based administration.
Oral suspension suitable for nasogastric administration in hospitalized or critically ill patients.